Kansas PKD Research and Translation Core Center

堪萨斯 PKD 研究与翻译核心中心

基本信息

  • 批准号:
    10686046
  • 负责人:
  • 金额:
    $ 76.36万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-15 至 2025-06-30
  • 项目状态:
    未结题

项目摘要

Project Summary – Overall The Kansas PKD Research and Translation Core Center (RTCC) is comprised of an Administrative Core and three innovative Biomedical Research Cores: Core 1: Biomarkers, Biomaterials, and Cellular Models; Core 2: Rodent Models & Drug Testing; and Core 3: Clinical Research. The Kansas RTCC also offers an Educational Enrichment Program and an internal Pilot Grant Program in partnership with the KU Cancer Center. The mission of the PKD Center is to promote PKD research by providing both innovative and essential reagents, biomaterials, and service to the national PKD research community for the advancement of our understanding of disease mechanisms, the discovery of biomarkers and therapeutic targets and the development of clinical trials to improve patient outcomes. The Specific Aims of the Kansas PKD RTCC are: Aim 1) To support PKD researchers nationally by developing innovative biomedical research cores. This will be accomplished by developing the expertise, reagents and resources required to bring the best new technologies to PKD research to meet the needs of the greater PKD research community; by leveraging existing institutional shared resources to expand our capability, efficiency, and effectiveness; and by developing tools to support clinical research and establish collaborations both regionally and nationally to develop a multi-institutional ADPKD clinical trials network. Aim 2) To develop a skilled, collaborative, multidisciplinary basic science and clinical PKD research investigator base. This will be accomplished by building on our broad multidisciplinary research base and continuing to recruit new investigators from outside the PKD field by offering an innovative pilot grant program that will attract new investigators to the field, and by providing new investigators, nationally, with research support for core services, new technologies, educational opportunities, and an open and collaborative research environment that will help them succeed. Aim 3) To enhance the PKD research environment with educational programs to support ongoing projects and to develop new research directions. The research environment will be enhanced through a seminar program, Summer Student Enrichment Program, PKD lab meetings, PKD methods workshops, Research Methods and Advanced Technologies Program, professional development seminar series, patient-oriented activities, and by participating in the consortium-wide annual symposium. Aim 4) To develop partnerships regionally and nationally and to build teams to serve as a resource for the greater PKD research community. Inter-institutional partnerships will provide local and national infrastructure support, new research technologies, increased numbers of patients involved in clinical trials, and research collaborators for the development of new research opportunities by attracting investigators from other fields into PKD research from collaborating sites within the PKD Research Consortium and with cooperating institutions nationwide, broadening opportunities beyond what any single institution can provide.
项目摘要-整体

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

DARREN P. WALLACE其他文献

DARREN P. WALLACE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('DARREN P. WALLACE', 18)}}的其他基金

Kansas PKD Research and Translation Core Center
堪萨斯 PKD 研究与翻译核心中心
  • 批准号:
    10475035
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Biomedical Research Core 1 - Biomarkers, Biomaterials, and Cellular Models Core
生物医学研究核心 1 - 生物标志物、生物材料和细胞模型核心
  • 批准号:
    10475041
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Biomedical Research Core 1 - Biomarkers, Biomaterials, and Cellular Models Core
生物医学研究核心 1 - 生物标志物、生物材料和细胞模型核心
  • 批准号:
    10214614
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Additional Informatics support on U54 Clinical Core
U54 临床核心的附加信息学支持
  • 批准号:
    10890529
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Biomedical Research Core 1 - Biomarkers, Biomaterials, and Cellular Models Core
生物医学研究核心 1 - 生物标志物、生物材料和细胞模型核心
  • 批准号:
    10059766
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Biomedical Research Core 1 - Biomarkers, Biomaterials, and Cellular Models Core
生物医学研究核心 1 - 生物标志物、生物材料和细胞模型核心
  • 批准号:
    10686060
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
Additional informatics support on U54 Clinical Core
U54 临床核心的附加信息学支持
  • 批准号:
    10685724
  • 财政年份:
    2020
  • 资助金额:
    $ 76.36万
  • 项目类别:
CORE--BIOMATERIALS
核心--生物材料
  • 批准号:
    7923963
  • 财政年份:
    2009
  • 资助金额:
    $ 76.36万
  • 项目类别:
Role of Periostin in Polycystic Kidney Disease
骨膜素在多囊肾病中的作用
  • 批准号:
    9125814
  • 财政年份:
    2009
  • 资助金额:
    $ 76.36万
  • 项目类别:
Role of Periostin in Polycystic Kidney Disease
骨膜素在多囊肾病中的作用
  • 批准号:
    8129499
  • 财政年份:
    2009
  • 资助金额:
    $ 76.36万
  • 项目类别:

相似海外基金

Immune Cell and Epithelial Cell Interactions in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中免疫细胞和上皮细胞的相互作用
  • 批准号:
    10749617
  • 财政年份:
    2023
  • 资助金额:
    $ 76.36万
  • 项目类别:
Mechanisms driving Autosomal Dominant Polycystic Kidney Disease: The novel role of the RNA-binding protein ANKHD1.
常染色体显性多囊肾病的驱动机制:RNA 结合蛋白 ANKHD1 的新作用。
  • 批准号:
    MR/T04201X/2
  • 财政年份:
    2023
  • 资助金额:
    $ 76.36万
  • 项目类别:
    Fellowship
CRISPR-Cas Editing as a Genetic Cure for Autosomal Dominant Polycystic Kidney Disease
CRISPR-Cas 编辑作为常染色体显性多囊肾病的基因治疗
  • 批准号:
    10822502
  • 财政年份:
    2023
  • 资助金额:
    $ 76.36万
  • 项目类别:
Modulation of cyst growth in renal tissue from patients with autosomal dominant polycystic kidney disease in a human tissue-based 3D-in-vivo-model
基于人体组织的 3D 体内模型中常染色体显性多囊肾病患者肾组织囊肿生长的调节
  • 批准号:
    496538332
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
    Research Grants
Mechanisms driving cardiac dysfunction in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病心脏功能障碍的驱动机制
  • 批准号:
    10443441
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
WNT signaling in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中的 WNT 信号传导
  • 批准号:
    10387670
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
An investigation into the functional role of the RhoGAP protein SH3BP1/ARHGAP43 in Autosomal Dominant Polycystic Kidney Disease
RhoGAP 蛋白 SH3BP1/ARHGAP43 在常染色体显性多囊肾病中的功能作用研究
  • 批准号:
    MR/W015579/1
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
    Fellowship
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
  • 批准号:
    10534531
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
Feasibility study of empagliflozin in patients with autosomal dominant polycystic kidney disease
恩格列净治疗常染色体显性多囊肾病的可行性研究
  • 批准号:
    10684097
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
WNT signaling in Autosomal Dominant Polycystic Kidney Disease
常染色体显性多囊肾病中的 WNT 信号传导
  • 批准号:
    10609804
  • 财政年份:
    2022
  • 资助金额:
    $ 76.36万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了